103 completed, 27 terminated, 7 unknown, 7 withdrawn. 153 Phase 1, 50 Phase 2.
Follow Velcade: new trials by email Literature Review of Velcade trials Research Report on Velcade
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Isatuximab, Iberdomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 88 | 2026-09-03 | 2026-09-03 |
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-08-17 |
| Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma Venetoclax, Dexamethasone, Bortezomib - T-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-06-05 | 2026-08-12 |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 10 | 2022-10-07 | 2026-05-13 |
| Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 49 | 2022-08-11 | 2026-10-16 |
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Xia Zhongjun | 42 | 2022-07-25 | 2024-06-17 |
| Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease Isatuximab, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | Washington University School of Medicine | 1 | 2022-04-01 | 2024-02-09 |
| Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Terminated | Abdullah Khan | 1 | 2021-09-27 | 2024-06-06 |
| Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis Bortezomib, Cyclophosphamide, Dexamethasone - AL Amyloidosis | Phase 1 | Active not recruiting | Emory University | 11 | 2021-04-28 | 2026-07-14 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma Bortezomib, Metformin Hydrochloride, Nelfinavir Mesylate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 9 | 2019-04-17 | 2024-08-22 |
| Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma Bortezomib, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-01-25 | 2023-09-26 | |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Cannabidiol, Bortezomib, Leucovorin - Cancer of Pancreas, Cancer of Liver | Phase 1 / Phase 2 | Unknown | Leaf Vertical Inc. | 160 | 2019-01-15 | 2018-07-31 |
| Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2018-09-18 | 2026-10-22 | |
| Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Oncopeptides AB | 56 | 2018-04-12 | 2022-12-19 |
| Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) Daratumumab, Cyclophosphamide, Bortezomib - Multiple Myeloma | Phase 1 | Unknown | National University of Ireland, Galway, Ireland | 18 | 2016-11-01 | 2018-03-29 |
| A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma CC-220, Dexamethasone, Daratumumab - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Celgene | 466 | 2016-10-14 | 2026-03-20 |
| Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma Bortezomib, Ruxolitinib - Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin | Phase 1 | Completed | University of Michigan Rogel Cancer Center | 15 | 2016-05-12 | 2021-12-20 |
| Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation lenalidomide, bortezomib, cyclophosphamide - Plasma Cell Myeloma | Phase 1 | Completed | Sanofi | 90 | 2015-09-30 | 2024-01-29 |
| Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Completed | University of Southern California | 14 | 2015-08-21 | 2023-08-14 |
Showing 20 of 153. Sign in to see all of them.
Multiple Myeloma (64) · Lymphoma, Mantle-Cell (21) · Leukemia, Myeloid, Acute (18) · Lymphoma, Non-Hodgkin (16) · Lymphoma (15) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, Follicular (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Lymphoma, Large B-Cell, Diffuse (12) · Recurrence (11) · Lymphoma, B-Cell, Marginal Zone (10) · Neoplasms, Plasma Cell (10) · Leukemia (9) · Lymphoma, Large-Cell, Anaplastic (9) · Waldenstrom Macroglobulinemia (9)
National Cancer Institute (NCI) (33) · M.D. Anderson Cancer Center (12) · Dana-Farber Cancer Institute (7) · Emory University (6) · Mayo Clinic (5) · City of Hope Medical Center (4) · UNC Lineberger Comprehensive Cancer Center (4) · Massachusetts General Hospital (3) · University of Michigan Rogel Cancer Center (3) · Case Comprehensive Cancer Center (2) · Celgene (2) · E. Steve Woodle (2) · Georgetown University (2) · Masonic Cancer Center, University of Minnesota (2) · Millennium Pharmaceuticals, Inc. (2)
United States (132) · France (6) · Spain (6) · Canada (5) · Italy (4) · United Kingdom (4) · Australia (3) · Germany (2) · Israel (2) · Japan (2) · South Korea (2) · Brazil (1) · China (1) · Czechia (1) · Ireland (1)
Irene Ghobrial, MD (3) · Arkadiusz Dudek, MD (2) · Arlene Siefker-Radtke, MD (2) · Beata Holkova, MD (2) · John P Leonard, MD (2) · Michael Pishvaian, MD PhD (2) · Paul Richardson, MD (2) · Sagar Lonial, MD (2) · Thomas C. Shea, MD (2) · Abdullah M Khan, MBBS, MSc (1) · Alex Adjei (1) · Alexander K. Stewart, M.D. (1)
PMID 18327587, PMID 19498019, PMID 19860608, PMID 20582937, PMID 21345726, PMID 21562045, PMID 21596852, PMID 21816833, PMID 21911830, PMID 21990396, PMID 22394984, PMID 22535574, PMID 22566605, PMID 22653976, PMID 23040438, PMID 23256542, PMID 24075534, PMID 24991834, PMID 25202139, PMID 26139427, PMID 26248505, PMID 26659919, PMID 26784138, PMID 27040320, PMID 27843120, PMID 28103725, PMID 28341300, PMID 28637662, PMID 28684537, PMID 29094232, PMID 29260507, PMID 29296805, PMID 30297385, PMID 30501870, PMID 31113777, PMID 31120355, PMID 31201169, PMID 31358485, PMID 31375516, PMID 31456261, PMID 31538230, PMID 31723767, PMID 32078124, PMID 33112184, PMID 33357482, PMID 35876974, PMID 36184192, PMID 36209764, PMID 36882409, PMID 37316728
U01CA062505 (4), U01CA076576 (4), U01CA062491 (3), U01CA097452 (3), 2009 (2), N01CM62204 (2), N01CM62208 (2), P30CA014089 (2), P30CA015083 (2), P30CA016058 (2), P30CA043703 (2), U01CA062487 (2), U01CA062502 (2), U01CA069853 (2), U01CA069912 (2)